Literature DB >> 14522884

A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis.

Xue-Ming Xu1, Yixin Chen, Jinguo Chen, Shanmin Yang, Feng Gao, Charles B Underhill, Karen Creswell, Lurong Zhang.   

Abstract

A number of hyaluronan (HA) binding proteins such as soluble CD44, receptor for hyaluronan-mediated motility (RHAMM), and metastatin inhibit tumor growth and metastasis. To determine whether the HA binding motif is the element responsible for the antitumor effect of this family of proteins, we examined the biological activity of a 42-amino acid peptide (designated as BH-P) that contains three HA binding motifs [B(X(7))B] from human brain HA binding protein. In initial experiments with cultured cells, we found that synthetic BH-P inhibited the proliferation and colony formation of tumor cells. It also blocked the growth of tumors on the chorioallantoic membranes of 10-day chicken embryos. In addition, MDA-435 melanoma cells that had been transfected with an expression vector for BH-P grew at a slower rate in nude mice than the vector-alone transfectants. Final studies revealed that the BH-P could activate caspase-8, caspase-3, and poly(ADP-ribose) polymerase and trigger the apoptosis of tumor cells. Taken together, these results suggest that the HA binding motif that is present in HA binding proteins may be responsible for the antitumor effect exerted by the members of this family.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522884

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  The role of deubiquitinating enzymes in apoptosis.

Authors:  Suresh Ramakrishna; Bharathi Suresh; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2010-08-21       Impact factor: 9.261

2.  Role of CD44 and its v7 isoform in staphylococcal enterotoxin B-induced toxic shock: CD44 deficiency on hepatic mononuclear cells leads to reduced activation-induced apoptosis that results in increased liver damage.

Authors:  Robert J McKallip; Michael Fisher; Ursula Gunthert; Andras K Szakal; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Pigment epithelium-derived factor binds to hyaluronan. Mapping of a hyaluronan binding site.

Authors:  S Patricia Becerra; L Alberto Perez-Mediavilla; John E Weldon; Silvia Locatelli-Hoops; Preenie Senanayake; Luigi Notari; Vicente Notario; Joe G Hollyfield
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

4.  Lymph node biophysical remodeling is associated with melanoma lymphatic drainage.

Authors:  Nathan Andrew Rohner; Jacob McClain; Sara Lydia Tuell; Alex Warner; Blair Smith; Youngho Yun; Abhinav Mohan; Manuela Sushnitha; Susan Napier Thomas
Journal:  FASEB J       Date:  2015-07-15       Impact factor: 5.191

5.  Proteoglycans in Normal and Healing Skin.

Authors:  Margaret Mary Smith; James Melrose
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

6.  The inhibition of neutrophil-endothelial cell adhesion by hyaluronan independent of CD44.

Authors:  C A S Alam; M P Seed; C Freemantle; J Brown; M Perretti; M Carrier; A Divwedi; D C West; S Gustafson; P R Colville-Nash; D A Willoughby
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

Review 7.  Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers.

Authors:  Hideo Shigeishi; Koichiro Higashikawa; Masaaki Takechi
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-28       Impact factor: 4.553

8.  Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.

Authors:  Alla V Ivanova; Chandra M V Goparaju; Sergey V Ivanov; Daisuke Nonaka; Christina Cruz; Amanda Beck; Fulvio Lonardo; Anil Wali; Harvey I Pass
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

9.  Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase.

Authors:  Joshua I Park; Limin Cao; Virginia M Platt; Zhaohua Huang; Robert A Stull; Edward E Dy; Jeffrey J Sperinde; Jennifer S Yokoyama; Francis C Szoka
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

Review 10.  Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.

Authors:  Virginia M Platt; Francis C Szoka
Journal:  Mol Pharm       Date:  2008-06-03       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.